Literature DB >> 31448426

Association of CTLA-4, TNF alpha and IL 10 polymorphisms with susceptibility to hepatocellular carcinoma.

Jia-Jia Wang1, Zhi-Bin Wang1, Tai-Chang Tan1.   

Abstract

Our aim was to evaluate the association of genetic polymorphisms of immunoregulatory molecules with susceptibility to hepatocellular carcinoma (HCC). The polymorphisms in CTLA-4 (-318 T/C, CT60 G/A), TNF (-238 G/A, -308 G/A) and IL10 (-592 C/A, -819 C/T) were genotyped by PCR and DNA sequencing. The functional relevance of the polymorphisms was examined by ELISAs, in vitro lymphocyte proliferation assay and cytotoxic assay. The CTLA-4 -318 TC/TT, CTLA-4 CT60 GG, IL10 -592 CA and -819 CT/TT variants, CTLA-4 -318 T and IL 10 -819 T alleles were positively associated with HCC risk (P < .05). While TNF -238 AA variant, TNF -238 A allele were associated with decreased risk of HCC (P < .05). Furthermore, combinations of CTLA-4 -318 TC/TT and TNF -238 GG/GA; CTLA-4 -318 TC/TT and IL 10 -819 CC; CTLA-4 -318 CC and IL 10 -819 CT/TT in patients with HCC were statistically significant (P < .05). Peripheral blood mononuclear cells (PBMCs) carrying -318 TC/TT genotypes exhibited significantly lower proliferation rates, decreased IL-2, IL-4 levels, fewer cytolytic activities and elevated TGF-β levels. For IL 10 -819 C/T, the CC genotype was significantly associated with higher proliferation rate, decreased TGF-β, IL-10 levels and higher cytolytic activities (P < .05). For TNF -238 G/A, the AA genotype only had association with serum IL-2, IL-4 (P < .05). In addition, we also found that CTLA-4 -318 T/C, IL-10 -819 T/C variants, combinations of CTLA-4 -318 CC with IL 10 -819 CT or TT, CTLA-4 -318 TC or TT with IL 10 -819 CT or TT were associated with the severity of HCC. These findings suggest that CTLA-4 -318 TC/TT and IL 10 -819 CT/TT could promote the pathogenesis of HCC, which might be related with down-regulation of Th1/Th2-type cytokines and/or up-regulation of Th3-type cytokines.
© 2019 The Scandinavian Foundation for Immunology.

Entities:  

Keywords:  CTLA-4; cytokines; genetic polymorphisms; hepatocellular carcinoma

Mesh:

Substances:

Year:  2019        PMID: 31448426     DOI: 10.1111/sji.12819

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  5 in total

1.  Data Mining and Systems Pharmacology to Elucidate Effectiveness and Mechanisms of Chinese Medicine in Treating Primary Liver Cancer.

Authors:  Zhen Zhang; Jun-Wei Li; Pu-Hua Zeng; Wen-Hui Gao; Xue-Fei Tian
Journal:  Chin J Integr Med       Date:  2021-08-25       Impact factor: 1.978

Review 2.  Immune Checkpoint Molecules-Inherited Variations as Markers for Cancer Risk.

Authors:  Marta Wagner; Monika Jasek; Lidia Karabon
Journal:  Front Immunol       Date:  2021-01-14       Impact factor: 7.561

3.  Direct Relationship between Interleukin-10 Gene Polymorphism and Hepatocellular Carcinoma Complicated by Direct Acting Antiviral Treatment of Hepatitis C Virus.

Authors:  Samar Ebrahim Ghanm; Nashwa Abuel-Fetuh Shebl; Ibrahim El Tantawy El Sayed; Hamed Mohamed Abdel-Bary; Basant Farid Saad; Warda Othman Saad
Journal:  Asian Pac J Cancer Prev       Date:  2021-10-01

4.  Genetic polymorphisms and protein levels in vocal fold leukoplakia: a systematic review.

Authors:  C P Campello; M F B Lima-Silva; E L S de Lima; G R S Nunes; H A M Silva; E Dellalibera; L R P B de Britto; C A A Lemos; M T C Muniz
Journal:  Braz J Med Biol Res       Date:  2022-03-11       Impact factor: 2.590

5.  Association of CTLA-4 and IL-4 polymorphisms in viral induced liver cancer.

Authors:  Maria Shabbir; Yasmin Badshah; Khushbukhat Khan; Janeen H Trembley; Areeb Rizwan; Fatima Faraz; Syeda Alveena Shah; Mahrukh Farooqi; Naeem Mahmood Ashraf; Tayyaba Afsar; Ali Almajwal; Nawaf W Alruwaili; Suhail Razak
Journal:  BMC Cancer       Date:  2022-05-07       Impact factor: 4.638

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.